Aim: To evaluate efficacy and safety of everolimus combined with long-acting octreotide in heavily pretreated patients with NETs. To determine predictive factors for everolimus efficacy. Methods: 33 pts with progressive well differentiated NETs (G1,G2) were treated with everolimus 10 mg q.d. combined with octreotide LAR 30-40 mg till progression or intolerable toxicity. All pts were evaluable for efficacy and toxicity. The mean age was 54 years (25-72), 11 male, 22 female. The most of pts had pancreatic NETs-13 (39%) pts. There were 19 (57,6%) NETs of foregut origin, 8 (24,2%) NETs of midgut origin, 1 (3%) hindgut NET and 5 (15,2%) of unknown origin. 21 pts had 0-1-2 prior lines of chemotherapy and 12 pts were heavily pretreated with more than 3 lines of chemotherapy. Primary tumor was resected in 16 (48,5%) pts. Previous treatment included interferon α, octreotide LAR, XelOx, EP and various combinations of temozolomide, paclitaxel and fluoropyrimidines. Results: There was 1 partial response (3%), 25 pts had stable disease (76%) and 7 pts (21%) had progressive disease. The median progression-free survival (PFS) reached 8.6 months (95% CI: 4.2-13). In a subgroup of heavily pretreated pts with more than 3 lines of chemotherapy median PFS rate was 3.2 months (95% CI: 1.3-5
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